Circadian owns Vegenics

By Dylan Bushell-Embling
Thursday, 14 August, 2008

Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.

Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.

Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.

Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.

Content from other channels on our network

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon

Calibration explained: principles, processes and modern reporting

Ensuring reliable level measurement in tanks with internal obstructions

Siemens announces turnkey industrial edge AI solution

Biotechnology innovations in latest $6.9m industry grant funding

Australia and US investing in additional critical minerals projects

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

NSW closes EV gaps in regional areas

Call for 10c increase on container return schemes

Water transition key at Global Water Summit 2026

Circadian owns Vegenics

Proposed Australian trial eyes up blood testing for Alzheimer's

Applications open for $300K pandemic therapeutics fellowships

CTA granted for CAR-T cell therapy for multiple myeloma

Content from other channels on our network